SALT LAKE CITY, UT / ACCESSWIRE / October 1, 2024 / KindlyMD, Inc. ("KindlyMD" or the "Company") (NASDAQ:KDLY), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, today announced that KindlyMD's CEO, Tim Pickett, is scheduled to participate in the following October 2024 investor conferences.
Benzinga Cannabis Capital Conference
Dates: October 8-9, 2024
Location: Marriott Magnificent Mile, Chicago, IL
Panel Day and Time: October 9th at 12:50 p.m. MT
Panel: The Medical Cannabis Experience: Best Practices For Patient Access, Care And Loyalty
Webcast: https://investors.kindlymd.com/events-presentations
LD Micro Main Event XVII
Dates: October 28-30, 2024
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA
Presentation Day and Time: October 29th at 12:30 p.m. MT
Presentation Location: Track 4
Webcast: https://investors.kindlymd.com/events-presentations
To schedule a one-on-one investor meeting with Mr. Pickett, please contact your representatives at Benzinga, LD Micro, or email KCSA Strategic Communications at This email address is being protected from spambots. You need JavaScript enabled to view it..
About KindlyMD
KindlyMD™️ is a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies to offer patients comprehensive care and reduce the addiction and dependency of opioid use in the U.S. KindlyMD currently operates four centers including the largest alternative pain treatment center in Utah. With a focus on holistic pain management through its specialty outpatient clinical services, including, where appropriate, the recommendation of medical cannabis by KindlyMD healthcare providers, KindlyMD is providing better patient health outcomes.
For more information, please visit www.kindlymd.com.
Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
(212) 896-1254
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.05 |
| Daily Change: | -0.06 -5.41 |
| Daily Volume: | 41,629 |
| Market Cap: | US$6.280M |
November 13, 2024 October 29, 2024 October 08, 2024 August 14, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
